Natera (NASDAQ:NTRA) Director Sells $4,132,500.00 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the sale, the director directly owned 4,250 shares in the company, valued at $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Price Performance

NASDAQ NTRA traded up $1.17 on Friday, reaching $261.91. The company had a trading volume of 3,411,707 shares, compared to its average volume of 1,476,758. The firm has a market cap of $37.51 billion, a price-to-earnings ratio of -160.68 and a beta of 1.56. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $271.47. The business has a 50 day moving average of $212.73 and a two-hundred day moving average of $215.87.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NTRA shares. UBS Group set a $260.00 target price on shares of Natera in a research report on Wednesday. Royal Bank Of Canada began coverage on shares of Natera in a report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price objective on the stock. BTIG Research set a $275.00 target price on Natera and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $259.22.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Reflection Asset Management purchased a new position in Natera in the fourth quarter valued at about $29,000. Palladiem LLC bought a new position in Natera during the fourth quarter valued at $31,000. Bank of Jackson Hole Trust increased its position in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after buying an additional 83 shares during the last quarter. International Assets Investment Management LLC raised its stake in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Natera during the 4th quarter valued at $39,000. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.